

# Programme at a glance Saturday, 05 June 2021

## Programme at a glance - Saturday, 05 June 2021

	Hall A3-7 (Plenary)	Hall Dublin	Hall A8	Hall Helsinki	Hall Budapest	Hall New York	Hall London	Hall A1	Virtual Hall 1	Virtual Hall 2	Mini-Orals Hall	Moderated Mini-Orals
08.45 - 12.25		CEPD 1 Primary & secondary glomerulonephritis, vasculitis, autoimmune diseases	CEPD 2 Hypertension, diabetes, cardiovascular diseases in CKD	CEPD 3 CKD and bone mineral disorders in CKD		CEPD 4 Haemo- and peritoneal dialysis	HC1 Hands-on Course Renal Molecular Pathology	HC 2 Hands-on Course Vascular Access			Mini-Orals	
12.25 - 13.00	Lunch break											
13.00 - 16.40			CEPD 5 Kidney transplantation		CEPD 6 Acute Kidney Injury	CEPD 7 Electrolytes and uraemia	CEPD 8 Nephropathology	HC 2 Hands-on Course Vascular Access			Mini-Orals	
16.40 - 17.00	Coffee break											
17.00 - 18.15	Welcome Ceremony + Lecture Chris Bertram "Too late for 2°C? From the Paris agreement to the climate of tomorrow"										Mini-Orals	
All day	Virtual Exhibition open											
	Fluids and electrolytes, tubular transport, physiology Hereditary disorders, development, pregnancy, paediatric nephrology Glomerular diseases and general clinical nephrology Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging End Stage Renal Disease and dialysis			Home therapies, peritoneal dialysis Transplantation and immunology Hypertension, diabetes, vascular diseases Acute Kidney Injury and intensive care nephrology Industry Sponsored Symposia			Hypertension Virtual Exhibition Other					

# Programme at a glance Sunday, 06 June 2021

## Programme at a glance - Sunday, 06 June 2021

	Hall A3-7 (Plenary)	Hall Dublin	Hall A8	Hall Helsinki	Hall Budapest	Hall New York	Hall London	Hall A1	Virtual Hall 1	Virtual Hall 2	Mini-Orals Hall	Moderated Mini-Orals
08.00 - 09.30	S 3.1 COVID-19 pandemic	S 4.1 New treatment targets to halt CKD progression	S 3.4 KDIGO clinical practice guideline on diabetes management in CKD	S 3.2 ERA-EDTA Registry	FC 30 Transplantation & New Technologies	FC 18 Big data & Nephrology	FC 12 Basic Science in AKI	FC 28 Dialysis: Quality of Life	S 3.6 Future scenarios for renal disease	FC 08 Hypertension & Oncics	Mini-Orals	
9.30 - 9.45	Moderated Mini-orals and coffee break											
9.45 - 10.45		ISS 1.1 Proteinuria Treatment Targets in FSGS and IgA Nephropathy (Trevi Therapeutics)		ISS 1.3 Diagnosis, Genetics and Pathophysiology of Alport Syndrome (Reata Pharmaceuticals, Inc)	ISS 1.2 Understanding the APOE1 Connection in Proteinuric Kidney Disease (Vertex Pharmaceuticals)	ISS 1.4 Hyperkalaemia in CKD: An Interactive Discussion on Current Management (AstraZeneca)	ISS 1.5 A new perspective in the management of aTTP: The Nephrologist Approach (Sanofi Genzyme)	ISS 1.6 Renal Denervation - A Different Tool for Hypertension Care (Medtronic)	ISS 1.7 Membrane Innovation: from bench to bedside (PACE-CME: Physicians Academy for Cardiovascular Education)	ISS 1.8 Expert Case Challenge SGLT2i in CKD: How to overcome clinical inertia? (PACE-CME: Physicians Academy for Cardiovascular Education)	Mini-Orals	MMO 1 Moderated Mini-Orals 1
10.45 - 11.30	PL1 Anna Craba "Development of novel, mechanism-based therapies for kidney diseases"										Mini-Orals	
11.30 - 11.45	Coffee break											
11.45 - 13.15	S 0.1 Late breaking clinical trial	S 3.3 Hypertension treatment in special renal populations	S 6.1 News in peritoneal dialysis	S 2.1 Diagnosis and treatment of rare disease in children and adult CKD	S 7.1 Translational research in kidney transplant: From bench to bedside	FC 07 Interventions in CKD	FC 19 Anaemia: What Else?	FC 27 Dialysis: Heart & Vessels	S 1.4 Electrolytes: renal transport and endocrine control	FC 15 Fluid, GFR & Co.	Mini-Orals	
13.15 - 13.30	Lunch break											
13.30 - 14.30	S 0.8 N-PATH Project Presentation	ISS 1.9 CKD-MBD patient management - a clinical perspective (Vifor Pharma Management Ltd)	ISS 1.10 Hyperkalaemia and CKD: beyond potassium control (Vifor Pharma Management Ltd)	ISS 1.12 Advances in Autosomal Dominant Polycystic Kidney Disease: Improving patient care to slow disease progression (Sanofi Genzyme)	ISS 1.11 Nonsteroidal MRAs to improve outcomes in patients with T2D and CKD (BAYER AG)	ISS 1.13 A new approach for glomerulonephritis: Targeting the alternative complement pathway (Novartis Pharma AG)	ISS 1.4 IgA Nephropathy - Can We Improve Treatment Options for Patients? (Celliditas Therapeutics AB)	ISS 1.15 What's next for patients with lupus nephritis? (GlaxoSmithKline)	ISS 1.16 Frontiers in the Management of aHUS. (Alexion Pharmaceuticals, Inc.)	ISS 1.17 Anaemia of CKD: Challenging the status quo (Astellas Pharma Europe Ltd)	Mini-Orals	
14.30 - 15.00	Lunch break											
15.00 - 16.30	S 0.3 GIN highlight	S 3.2 News in glomerulonephritis treatment	S 5.5 Everyday issues in dialysis	S 4.6 New nutritional targets in CKD	S 9.2 What progress in AKI?	FC 04 Genes And Kidney	FC 08 The Virus and the Kidney	FC 17 Pathophysiological Pathways in CKD	S 2.3 Preeclampsia and kidney in 2021	FC 16 Surviving CKD	Mini-Orals	
16.30 - 17.30	Moderated Mini-orals and coffee break											
17.00 - 17.45	S 4.7 SGLT2-inhibitors in CKD without diabetes	S 4.5 Preventing kidney ageing	S 1.3 Phosphate and other minerals	S 3.3 Endocannabinoids and kidney	FC 32 Transplantation: Short- and long-term Outcomes	FC 22 Stop Diabetes	FC 26 Outcomes in PD	FC 1 Stones & Brain	S 9.5 Avoiding a crash landing of nephrology by creating awareness	FC 34 A Look In The Crystal Ball: Environment & Education	Mini-Orals	MMO 2 Moderated Mini-Orals 2
17.45 - 18.30	Virtual Exhibition open											
All day	Virtual Exhibition open											
	Fluids and electrolytes, tubular transport, physiology Hereditary disorders, development, pregnancy, paediatric nephrology Glomerular diseases and general clinical nephrology Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging End Stage Renal Disease and dialysis			Home therapies, peritoneal dialysis Transplantation and immunology Hypertension, diabetes, vascular diseases Acute Kidney Injury and intensive care nephrology Industry Sponsored Symposia			Hypertension Virtual Exhibition Other					

# Programme at a glance Monday, 07 June 2021

## Programme at a glance - Monday, 07 June 2021

	Hall A3-7 (Plenary)	Hall Dublin	Hall A8	Hall Helsinki	Hall Budapest	Hall New York	Hall London	Hall A1	Virtual Hall 1	Virtual Hall 2	Mini-Orals Hall	Moderated Mini-Orals
08.00 - 09.30		S 3.3 Membranous nephropathy: Insights from recent clinical trials	S 5.2 COVID-19 in haemodialysis patients	S 0.4 NDT & CKD Pearls	S 4.4 CKD and metabolic disorders: the common cognitive outcome	S 2.4 Networks and registries in rare kidney diseases	S 1.1 Acid-base balance in health and kidney disease	FC 13 AKI: The Good, the Bad & the Ugly	S 9.7 Climate change and health: the opinion of the younger generation	FC 29 Dialysis: Nutrition & Outcomes	Mini-Orals	
09.30 - 9.45	Moderated Mini-orals and coffee break											
09.45 - 10.45	ERA-EDTA General Assembly					ISS 2.1 Targeting CKD Patients' Quality of Life (Freemium Kabi)	ISS 2.2 When delays could lead to ESKD: Identifying and managing primary hyperoxaluria in clinical practice. (Alyftam Pharmaceuticals)	ISS 2.3 GLP-1RA in DKD: A new preventive challenge (Sponsored by an unrestricted educational grant from AstraZeneca Academy for Cardiovascular Education)	ISS 2.4 Estacalcin in clinical practice: more than just PTM? (Amgen)	ISS 2.5 Managing Albumin: a tool at clinicians' hand in managing Diabetic Nephropathy. (Werlen and Asahi-Kasei Pharma)	Mini-Orals	MMO 3 Moderated Mini-Orals 3
10.45 - 11.30		PL 2 Andrea Bellabio "A novel biological mechanism underlying renal cystogenesis and tumorigenesis"									Mini-Orals	
11.30 - 11.45	Coffee break											
11.45 - 13.15	S 4.8 Randomized trials - Slowing the progression of CKD	PD vs HD: similarities and differences, an endless debate	S 7.3 Transplant clinical medicine	S 3.7 Kidney stones	S 2.2 Extracellular vesicles and kidney diseases: from bio-markers to therapeutic bio-products	FC 10 Best Autoimmunity	FC 14 Prevention of AKI	FC 28 Bone & Outcomes in CKD	S 3.8 ANCA vasculitis: prognosis and treatment	FC 21 Fluids & More	Mini-Orals	
13.15 - 13.30	Lunch break											
13.30 - 14.30		ISS 2.6 Striking the right balance in ANCA-associated vasculitis (AAV) (Vifor Fresenius Medical Care Renal Pharma)	ISS 2.7 20 years of real world evidence data for Fabry Disease (Sanofi Genzyme)	ISS 2.9 Addressing gaps in patient care in rare inherited disorders: the role of the nephrologist (Chiesi Farmaceutici S.p.A)	ISS 2.8 RENAISSANCE of Patient PRIMA membrane for diversified hemodialysis (Toray Medical Co., Ltd)	ISS 2.10 Chronic kidney disease-associated pruritus (CKD-aP): addressing unmet needs in patients on dialysis (Vifor Fresenius Medical Care Renal Pharma Ltd)	ISS 2.11 Identifit - A paradigm shift in Transplanting the Untransplantable? (Hema Biopharma)	ISS 2.12 SGLT2 inhibitors: A practical guide (Sponsored by an unrestricted educational grant from AstraZeneca Academy for Cardiovascular Education)	ISS 2.13 Choosing the right therapy, place and time Integrating Patient Perspectives and Patient Reported Outcomes into Clinical Practice (Freemium Medical Care Deutschland GmbH)	ISS 2.14 GLP-1 receptor agonists and the Kidney (Novo Nordisk A/S)	Mini-Orals	
14.30 - 15.00	Lunch break											
15.00 - 16.30	S 8.5 KDIGO BP in CKD: controversial guideline 2021	S 5.3 Innovations in haemodialysis	S 3.5 Complicated Lupus Nephritis	S 4.2 Microbiome in CKD	S 3.8 Up-to-Date On Alport Syndrome	FC 23 Treat Diabetes	FC 33 Kids & Kidney	FC 03 Cyst & Cancer	S 3.9 The nephrotoxicity of commonly used medications: what is the evidence and what are the alternatives	FC 02 Cells & Immunity	Mini-Orals	
16.30 - 17.00	Moderated Mini-orals and coffee break											
17.00 - 17.45	S 6.2 Volume control in peritoneal dialysis	S 7.4 New mechanisms of graft damage in kidney transplantation	S 8.1 New concepts in cardiovascular disease in CKD patients	S 2.5 Updates on ADPKD	S 9.4 New aspects in AKI prevention and treatment	FC 24 DIALYSIS PATTERNS: WHAT'S NEW?	FC 05 Pathology meets clinics	FC 09 Basics & Clinics in glomerulonephritis	S 5.4 Volume and blood pressure control in dialysis	FC 31 Transplantation: Risks & Complications	Mini-Orals	MMO 4 Moderated Mini-Orals 4
17.45 - 18.30	Virtual Exhibition open											
All day	Virtual Exhibition open											
	Fluids and electrolytes, tubular transport, physiology Hereditary disorders, development, pregnancy, paediatric nephrology Glomerular diseases and general clinical nephrology Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging End Stage Renal Disease and dialysis			Home therapies, peritoneal dialysis Transplantation and immunology Hypertension, diabetes, vascular diseases Acute Kidney Injury and intensive care nephrology Industry Sponsored Symposia			Hypertension Virtual Exhibition Other					

# Programme at a glance Tuesday, 08 June 2021

## Programme at a glance - Tuesday, 08 June 2021

	Hall A3-7 (Plenary)	Hall Dublin	Hall A8	Hall Helsinki	Hall Budapest	Hall New York	Hall London	Hall A1	Virtual Hall 1	Virtual Hall 2	Mini-Orals Hall	Moderated Mini-Orals
08.30 - 10.00	S 3.4 Onconephrology	S 5.1 Nivolumab in the 21st century	S 7.2 Recent advances in kidney transplantation: focus on immunology	S 1.2 A new look at tubular functions	S 2.6 An integrated view of kidney: integrating clinical and genetic aspects	S 8.2 Diabetic nephropathy 2021	S 9.1 AKI in special situations	FC 11 Treatment & outcome of Glomerulonephritis	S 4.3 Uraemic toxicities	FC 25 Protect the membrane	Mini-Orals	
10.00 - 10.15	Coffee break											
10.15 - 11.00	PL 3 Anna Köllgen "Integrating multiomics data for a better understanding of kidney disease"										Mini-Orals	
11.00 - 11.15	Coffee break											
11.15 - 12.45	Nephrology Pearls										Mini-Orals	
Up to 12.45	Virtual Exhibition open											
	Fluids and electrolytes, tubular transport, physiology Hereditary disorders, development, pregnancy, paediatric nephrology Glomerular diseases and general clinical nephrology Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging End Stage Renal Disease and dialysis			Home therapies, peritoneal dialysis Transplantation and immunology Hypertension, diabetes, vascular diseases Acute Kidney Injury and intensive care nephrology Industry Sponsored Symposia			Hypertension Virtual Exhibition Other					